Letters

Advertisements for donepezil (Aricept) in the BMJ

BMJ 1997; 314 doi: http://dx.doi.org/10.1136/bmj.314.7093.1555 (Published 24 May 1997) Cite this as: BMJ 1997;314:1555
  1. Selena Gray, Senior lecturer in public health medicinea
  1. a University of Bristol, Bristol BS8 1TH
  2. b Stonebow Unit, County Hospital, Hereford HR1 2ER

    Advertisement suggests an unrealistic improvement in mental status

    Editor—I wish to express my anger and concern that advertising space on the wrapper around the clinical research edition of the BMJ (issues of 3 and 10 May) was sold to promote donepezil hydrochloride (Aricept). This is the first time that I have been aware of a promotion of this nature, and I find this form of advertising disturbing. While I appreciate that the BMJ generates necessary income from pharmaceutical companies and I can deal with advertisements within the journal, I find that to be faced by a paper strip on top of the BMJ that has to be forcefully removed before one can even read the contents page is irritating and intrusive. No doubt because of this, it is a successful marketing ploy and generates enormous amounts of income. As a general policy, however, I hope that the journal will reconsider accepting this type of advertisement, as I …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe